Skip to content
SANA·Nasdaq·US

Sana Biotechnology

Sana Biotechnology is a clinical-stage biotechnology company developing engineered cell therapies and genetic medicines. Its lead programs include hypoimmune stem-cell derived islet cell therapy for type 1 diabetes and in vivo CAR-T candidates for B-cell diseases.

Thematic Position

SANA

Relationship Groups

Partners1
Licensing1
Competitors19

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

1 ended relationship · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

government funding restrictionmandatory licensingmarch-in rights
U.S. government retains Bayh-Dole march-in rights over federally funded patents
SEC 10-QMay 11, 2026

The full regulatory passage is part of the Pro plan.

27 more · Regulatory and geopolitical insights are part of the Pro plan.